ESR1 and breast cancer: There was also no significant prognostic effect for p-eIF2α in the global population (Fig. 4a), in patients with the luminal breast cancer subtype (ER-positive and Her2-negative) (Fig. 4b), or in the Her2-positive subgroup (Fig. 4c).